13 research outputs found
Value of FDG-PET as a supporting biomarker for dementia with Lewy bodies at stages of early dopaminergic loss
Item does not contain fulltext1 p
Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies
Background: Striatal dopamine deficiency and metabolic changes are well-known phenomena in dementia with Lewy bodies and can be quantified in vivo by 123 I-Ioflupane brain single-photon emission computed tomography of dopamine transporter and 18 F-fluorodesoxyglucose PET. However, the linkage between both biomarkers is ill-understood. Objective: We used the hitherto largest study cohort of combined imaging from the European consortium to elucidate the role of both biomarkers in the pathophysiological course of dementia with Lewy bodies